Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Endexx Corporation (EDXC)
Cave Creek, AZ, US
Endexx Corporation operates within the health and wellness industry, specializing in the development and commercialization of products based on cannabidiol (CBD). The company offers a comprehensive range of CBD-infused items, including creams, oils, capsules, extracts, topicals, beverages, chocolates, and specialized formulations for pets. Additionally, it provides health and beauty care solutions derived from hemp. These products are specifically designed to offer therapeutic alleviation of pain and inflammation for both human and animal consumers. Endexx distributes its offerings through its dedicated e-commerce platform, cbdunlimited.com, as well as via other online retailers and brick-and-mortar stores. The entity was previously identified as CBD Unlimited, Inc., until it formally adopted the name Endexx Corporation in May 2020. Its corporate headquarters are located in Cave Creek, Arizona.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -66.67% | -93.33% | -85.71% | -97.55% | -99.74% | -99.91% | -99.67% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-57.6% Q1'25: -100.0% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+49.6% ★ Q1'25: -804.3% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-90.8%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-37.1%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'25: +257.3% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.2% Q1'25: +12.9% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-24.44× Q1'25: -0.33× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
|---|---|---|---|
| Revenue |
2.14M
est: 1.53M (+39.6%)
|
3.91M
est: 2.23M (+75.0%)
|
1.66M
est: 3.11M (-46.8%)
|
| EBITDA |
-3.65M
est: -1.34M (-172.4%)
|
-4.67M
est: -1.95M (-139.2%)
|
-613.4K
est: -2.72M (+77.5%)
|
| EBIT |
-3.67M
est: -1.34M (-174.0%)
|
-4.68M
est: -1.95M (-139.7%)
|
-613.4K
est: -2.72M (+77.5%)
|
| Net Income |
-4.90M
est: -5.21M (+6.0%)
|
-6.50M
est: -5.21M (-24.8%)
|
-3.40M
|
| SGA |
3.82M
est: 4.08M (-6.3%)
|
4.09M
est: 5.94M (-31.2%)
|
1.31M
est: 8.29M (-84.2%)
|
| EPS |
-0.01
est: -0.01 (+3.0%)
|
-0.01
est: -0.01 (-29.0%)
|
-0.01
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 10.00 | 9.90% | — | — | — | — | OO | FLORIDA | 2020-12-01 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Todd A. Davis | Director & Chief Executive Officer of CBD Unlimited Inc. | 125.0K | male |
| Brad Listermann | Interim Chief Executive Officer | — | — |
| Doug Williams | Chief Financial Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EDXC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
